See more : Goldplay Mining Inc. (AUCCF) Income Statement Analysis – Financial Results
Complete financial analysis of Aptorum Group Limited (APM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aptorum Group Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Atul Auto Limited (ATULAUTO.NS) Income Statement Analysis – Financial Results
- eFFECTOR Therapeutics, Inc. (EFTRW) Income Statement Analysis – Financial Results
- Aimflex Berhad (0209.KL) Income Statement Analysis – Financial Results
- HWGG Entertainment Limited (HWGG) Income Statement Analysis – Financial Results
- Papaya Growth Opportunity Corp. I (PPYA) Income Statement Analysis – Financial Results
Aptorum Group Limited (APM)
About Aptorum Group Limited
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 431.38K | 1.30M | 1.54M | 911.51K | 535.17K | 383.45K | 0.00 |
| Cost of Revenue | 420.81K | 1.22M | 1.46M | 1.02M | 794.55K | 318.01K | 58.90K |
| Gross Profit | 10.57K | 80.07K | 81.85K | -103.51K | -259.38K | 65.44K | -58.90K |
| Gross Profit Ratio | 2.45% | 6.18% | 5.31% | -11.36% | -48.47% | 17.07% | 0.00% |
| Research & Development | 5.20M | 9.22M | 10.87M | 11.59M | 6.94M | 3.10M | 2.50M |
| General & Administrative | 4.37M | 7.87M | 7.70M | 7.71M | 10.78M | 6.73M | 0.00 |
| Selling & Marketing | 48.98K | 98.08K | 95.95K | 55.43K | 0.00 | 0.00 | 0.00 |
| SG&A | 4.41M | 7.97M | 7.80M | 7.71M | 10.78M | 6.73M | 2.88M |
| Other Expenses | -9.60M | 404.54K | 623.64K | 877.39K | 220.89K | 560.71K | -257.18K |
| Operating Expenses | 10.57K | 17.59M | 19.29M | 20.17M | 17.94M | 10.39M | 5.63M |
| Cost & Expenses | 10.95M | 18.81M | 20.75M | 21.19M | 18.73M | 10.71M | 5.69M |
| Interest Income | 0.00 | 146.59K | 0.00 | 0.00 | 0.00 | 0.00 | 44.27K |
| Interest Expense | 121.15K | 146.59K | 93.60K | 243.63K | 3.70M | 4.46M | 0.00 |
| Depreciation & Amortization | 1.13M | 1.21M | 1.19M | 1.33M | 1.30M | 682.29K | 58.90K |
| EBITDA | -9.60M | -17.59M | -19.29M | 6.50M | -15.12M | -9.99M | -2.50M |
| EBITDA Ratio | -2,225.19% | -1,678.81% | -1,158.95% | -2,034.44% | -3,443.92% | -2,424.73% | 0.00% |
| Operating Income | -10.52M | -22.96M | -19.06M | -19.88M | -19.73M | -10.33M | -5.69M |
| Operating Income Ratio | -2,439.47% | -1,771.99% | -1,236.31% | -2,180.86% | -3,686.76% | -2,693.47% | 0.00% |
| Total Other Income/Expenses | 6.18M | 6.06M | -7.91M | 25.20M | -1.92M | -4.81M | 3.13M |
| Income Before Tax | -4.34M | -11.53M | -27.11M | 4.92M | -20.12M | -15.13M | -2.56M |
| Income Before Tax Ratio | -1,006.30% | -889.36% | -1,758.64% | 539.78% | -3,759.01% | -3,946.93% | 0.00% |
| Income Tax Expense | 0.00 | -6.21M | -1.83M | -1.51M | 737.64K | -302.76K | -14.05K |
| Net Income | -2.82M | -5.31M | -25.29M | 7.07M | -20.85M | -14.83M | -2.55M |
| Net Income Ratio | -654.80% | -410.10% | -1,640.21% | 775.29% | -3,896.84% | -3,867.97% | 0.00% |
| EPS | -0.62 | -14.89 | -7.22 | 2.03 | -7.19 | -5.31 | -0.85 |
| EPS Diluted | -0.62 | -14.89 | -7.22 | 2.00 | -7.19 | -5.31 | -0.85 |
| Weighted Avg Shares Out | 4.52M | 356.95K | 3.50M | 3.11M | 2.90M | 2.79M | 3.01M |
| Weighted Avg Shares Out (Dil) | 4.52M | 356.95K | 3.50M | 3.15M | 2.90M | 2.79M | 3.01M |
Az Aptorum Csoport jelentős előrelpsről szmolt be SACT-1 elnevezsű, a neuroblastoma kezelsre szolgl, gygyszerjelltjvel s az arra vonatkozan a tervek szerint 2020 msodik felben benyjtand IND-krelemmel kapcsolatosan
Az Aptorum Csoport tovbbi előrelpsről szmolt be a Staphylococcus aureus ltal okozott fertőzseknek egy virulenciagtlson alapul, nem baktericid, ALS-4 elnevezsű, kismretű gygyszermolekula-jelltjvel s az arra vonatkozan a tervek...
知臨集團宣布用於神經母細胞瘤的再利用候選藥物SACT-1取得顯著進展並計畫2020下半年提交IND
知臨集團宣布其用於治療由金黃色葡萄球菌所引起的感染的ALS-4小分子抗毒力（非殺菌）候選藥物的進一步正面資料，並可望於2020年下半年提交IND
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020
Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track Targeted For IND Submission in H2 2020
Source: https://incomestatements.info
Category: Stock Reports